Recent Insider Activity Suggests Potential Gains for Transmedics Group Inc (TMDX)

Transmedics Group Inc’s recently made public that its insider Ranganath Anil P. unloaded Company’s shares for reported $95903.0 on Jun 09 ’25. In the deal valued at $139.80 per share,686 shares were sold. As a result of this transaction, Ranganath Anil P. now holds 13,955 shares worth roughly $1.45 million.

Then, Basile Edward M sold 5,000 shares, generating $632,250 in total proceeds. Upon selling the shares at $126.45, the Director now owns 2,866 shares.

Before that, EDWARD BASILE bought 5,000 shares. Transmedics Group Inc shares valued at $632,250 were divested by the Director at a price of $126.45 per share.

JP Morgan downgraded its Transmedics Group Inc [TMDX] rating to a Neutral from a an Overweight in a research note published on December 17, 2024; the price target was decreased to $75 from $116. A number of analysts have revised their coverage, including Needham’s analysts, who decreased its forecast for the stock in late November from “a Buy” to “a Hold”. Oppenheimer also remained covering TMDX and reiterated its “an Outperform” recommendation on October 29, 2024. Needham maintained its rating on October 29, 2024. It rated TMDX as “a Buy”.

Price Performance Review of TMDX

On Monday, Transmedics Group Inc [NASDAQ:TMDX] saw its stock fall -5.71% to $103.61. Over the last five days, the stock has lost -11.35%. Transmedics Group Inc shares have fallen nearly -30.57% since the year began. Nevertheless, the stocks have risen 66.17% over the past one year.

How much short interest is there in Transmedics Group Inc?

A steep rise in short interest was recorded in Transmedics Group Inc stocks on 2025-06-13, dropping by -0.24 million shares to a total of 7.86 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 8.1 million shares. There was a decline of -3.1%, which implies that there is a negative sentiment for the stock.

The most recent change occurred on September 24, 2024 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $200 price target.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.